Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Assets (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Current Assets for 6 consecutive years, with $78.5 million as the latest value for Q3 2025.

  • Quarterly Current Assets rose 1774.34% to $78.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $78.5 million through Sep 2025, up 1774.34% year-over-year, with the annual reading at $98.5 million for FY2024, 592.78% up from the prior year.
  • Current Assets for Q3 2025 was $78.5 million at Inhibikase Therapeutics, down from $88.8 million in the prior quarter.
  • The five-year high for Current Assets was $98.5 million in Q4 2024, with the low at $4.2 million in Q3 2024.
  • Average Current Assets over 5 years is $37.8 million, with a median of $26.0 million recorded in 2022.
  • The sharpest move saw Current Assets plummeted 76.13% in 2024, then skyrocketed 1774.34% in 2025.
  • Over 5 years, Current Assets stood at $42.5 million in 2021, then tumbled by 42.62% to $24.4 million in 2022, then crashed by 41.69% to $14.2 million in 2023, then skyrocketed by 592.78% to $98.5 million in 2024, then dropped by 20.23% to $78.5 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $78.5 million, $88.8 million, and $94.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.